CRISPR-Cas9 patents: Don’t get confused!

Why not?
Because there are only t​hree foundational patent portfolios!

To protect its clients from infringement risks, genOway invested substantially to hold licenses under all three portfolios.

Consequently:

• Our customers are authorized to use CRISPR-Cas9 models for R&D (internal or commercial) with no need to acquire any additional license from any third party
• You can acquire the authorization from genOway for the internal development or usage of rodent models from third-party providers

^{Each granted patent is represented by a colored dot.}

The three foundational patent portfolios in the eukaryotic field are from:

1. Sigma-Aldrich, aka Merck, which covers any CRISPR-Cas9 system for modifying a target DNA leading to a double-stranded break (this system may be associated with an exogenous sequence to perform Knockin)
2. Berkeley, which covers any CRISPR-Cas9 system for modifying a target sequence along with at least one guide RNA
3. Broad, which covers any CRISPR-Cas9 system for modifying a target sequence, where the CRISPR system is delivered to cells in the form of vectors

Contact our licensing service for more information

Privacy & Confidentiality

We value your privacy. We will never give, lease, sell or otherwise disclose your personal information. Your project details will remain strictly confidential.